![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NADSYN1 |
Gene summary for NADSYN1 |
![]() |
Gene information | Species | Human | Gene symbol | NADSYN1 | Gene ID | 55191 |
Gene name | NAD synthetase 1 | |
Gene Alias | VCRL3 | |
Cytomap | 11q13.4 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q6IA69 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55191 | NADSYN1 | LZE2T | Human | Esophagus | ESCC | 6.54e-03 | 4.15e-01 | 0.082 |
55191 | NADSYN1 | LZE4T | Human | Esophagus | ESCC | 2.96e-25 | 8.24e-01 | 0.0811 |
55191 | NADSYN1 | LZE7T | Human | Esophagus | ESCC | 1.98e-04 | 2.50e-01 | 0.0667 |
55191 | NADSYN1 | LZE8T | Human | Esophagus | ESCC | 3.30e-56 | 1.46e+00 | 0.067 |
55191 | NADSYN1 | LZE20T | Human | Esophagus | ESCC | 3.06e-12 | 4.49e-01 | 0.0662 |
55191 | NADSYN1 | LZE21D1 | Human | Esophagus | HGIN | 2.30e-03 | 3.12e-01 | 0.0632 |
55191 | NADSYN1 | LZE22D1 | Human | Esophagus | HGIN | 1.26e-14 | 5.98e-01 | 0.0595 |
55191 | NADSYN1 | LZE22T | Human | Esophagus | ESCC | 1.13e-22 | 1.23e+00 | 0.068 |
55191 | NADSYN1 | LZE24T | Human | Esophagus | ESCC | 2.22e-34 | 7.15e-01 | 0.0596 |
55191 | NADSYN1 | LZE22D3 | Human | Esophagus | HGIN | 1.17e-02 | 6.66e-01 | 0.0653 |
55191 | NADSYN1 | LZE21T | Human | Esophagus | ESCC | 2.87e-07 | 5.89e-01 | 0.0655 |
55191 | NADSYN1 | P1T-E | Human | Esophagus | ESCC | 1.76e-17 | 7.25e-01 | 0.0875 |
55191 | NADSYN1 | P2T-E | Human | Esophagus | ESCC | 1.71e-96 | 1.72e+00 | 0.1177 |
55191 | NADSYN1 | P4T-E | Human | Esophagus | ESCC | 2.05e-40 | 7.44e-01 | 0.1323 |
55191 | NADSYN1 | P5T-E | Human | Esophagus | ESCC | 1.50e-14 | 1.84e-01 | 0.1327 |
55191 | NADSYN1 | P8T-E | Human | Esophagus | ESCC | 2.66e-109 | 2.18e+00 | 0.0889 |
55191 | NADSYN1 | P9T-E | Human | Esophagus | ESCC | 3.07e-17 | 4.02e-01 | 0.1131 |
55191 | NADSYN1 | P10T-E | Human | Esophagus | ESCC | 1.68e-16 | 2.64e-01 | 0.116 |
55191 | NADSYN1 | P11T-E | Human | Esophagus | ESCC | 8.43e-16 | 5.80e-01 | 0.1426 |
55191 | NADSYN1 | P12T-E | Human | Esophagus | ESCC | 5.27e-16 | 3.94e-01 | 0.1122 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000911720 | Esophagus | HGIN | nucleotide metabolic process | 92/2587 | 489/18723 | 1.11e-03 | 1.36e-02 | 92 |
GO:00091659 | Esophagus | HGIN | nucleotide biosynthetic process | 53/2587 | 254/18723 | 1.24e-03 | 1.49e-02 | 53 |
GO:000675320 | Esophagus | HGIN | nucleoside phosphate metabolic process | 93/2587 | 497/18723 | 1.25e-03 | 1.49e-02 | 93 |
GO:19012939 | Esophagus | HGIN | nucleoside phosphate biosynthetic process | 53/2587 | 256/18723 | 1.49e-03 | 1.73e-02 | 53 |
GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
GO:000916516 | Esophagus | ESCC | nucleotide biosynthetic process | 150/8552 | 254/18723 | 1.12e-05 | 1.06e-04 | 150 |
GO:190129316 | Esophagus | ESCC | nucleoside phosphate biosynthetic process | 151/8552 | 256/18723 | 1.15e-05 | 1.08e-04 | 151 |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
GO:0072525 | Liver | HCC | pyridine-containing compound biosynthetic process | 22/7958 | 32/18723 | 2.43e-03 | 1.18e-02 | 22 |
GO:0072524 | Liver | HCC | pyridine-containing compound metabolic process | 25/7958 | 38/18723 | 3.18e-03 | 1.47e-02 | 25 |
GO:0019359 | Liver | HCC | nicotinamide nucleotide biosynthetic process | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
GO:0019363 | Liver | HCC | pyridine nucleotide biosynthetic process | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
GO:000675318 | Oral cavity | OSCC | nucleoside phosphate metabolic process | 247/7305 | 497/18723 | 6.28e-07 | 8.96e-06 | 247 |
GO:000911719 | Oral cavity | OSCC | nucleotide metabolic process | 243/7305 | 489/18723 | 7.80e-07 | 1.09e-05 | 243 |
GO:19012938 | Oral cavity | OSCC | nucleoside phosphate biosynthetic process | 125/7305 | 256/18723 | 8.32e-04 | 4.41e-03 | 125 |
GO:00091658 | Oral cavity | OSCC | nucleotide biosynthetic process | 124/7305 | 254/18723 | 8.79e-04 | 4.63e-03 | 124 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012405 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa0124012 | Esophagus | ESCC | Biosynthesis of cofactors | 97/4205 | 153/8465 | 3.88e-04 | 1.35e-03 | 6.94e-04 | 97 |
hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
hsa012404 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa0124011 | Oral cavity | OSCC | Biosynthesis of cofactors | 88/3704 | 153/8465 | 3.84e-04 | 1.20e-03 | 6.12e-04 | 88 |
hsa0124021 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
hsa0124031 | Oral cavity | LP | Biosynthesis of cofactors | 57/2418 | 153/8465 | 1.17e-02 | 3.91e-02 | 2.52e-02 | 57 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NADSYN1 | SNV | Missense_Mutation | novel | c.214G>T | p.Ala72Ser | p.A72S | Q6IA69 | protein_coding | tolerated(0.24) | benign(0.009) | TCGA-A8-A082-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
NADSYN1 | SNV | Missense_Mutation | c.820G>C | p.Asp274His | p.D274H | Q6IA69 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
NADSYN1 | SNV | Missense_Mutation | rs766142745 | c.1472T>G | p.Val491Gly | p.V491G | Q6IA69 | protein_coding | deleterious(0.01) | benign(0.25) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
NADSYN1 | SNV | Missense_Mutation | novel | c.62G>A | p.Gly21Asp | p.G21D | Q6IA69 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0GZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
NADSYN1 | SNV | Missense_Mutation | rs766142745 | c.1472N>G | p.Val491Gly | p.V491G | Q6IA69 | protein_coding | deleterious(0.01) | benign(0.25) | TCGA-D8-A1X9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
NADSYN1 | SNV | Missense_Mutation | c.1789N>A | p.Glu597Lys | p.E597K | Q6IA69 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
NADSYN1 | SNV | Missense_Mutation | rs766142745 | c.1472T>G | p.Val491Gly | p.V491G | Q6IA69 | protein_coding | deleterious(0.01) | benign(0.25) | TCGA-E9-A227-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
NADSYN1 | SNV | Missense_Mutation | novel | c.1738N>A | p.Asp580Asn | p.D580N | Q6IA69 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-C5-A7X5-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
NADSYN1 | SNV | Missense_Mutation | novel | c.58N>C | p.Glu20Gln | p.E20Q | Q6IA69 | protein_coding | tolerated(0.12) | benign(0.174) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
NADSYN1 | SNV | Missense_Mutation | c.280N>T | p.Asn94Tyr | p.N94Y | Q6IA69 | protein_coding | deleterious(0.01) | probably_damaging(0.979) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |